|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
DE2010115A1
(de)
|
1970-03-04 |
1971-09-16 |
Farbenfabriken Bayer Ag, 5090 Leverkusen |
Verfahren zur Herstellung von Mikrogranulaten
|
|
JPS523342B2
(OSRAM)
|
1972-01-26 |
1977-01-27 |
|
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4201860A
(en)
|
1978-05-09 |
1980-05-06 |
Bristol-Myers Company |
Purine derivatives
|
|
US4384975A
(en)
|
1980-06-13 |
1983-05-24 |
Sandoz, Inc. |
Process for preparation of microspheres
|
|
US4389330A
(en)
|
1980-10-06 |
1983-06-21 |
Stolle Research And Development Corporation |
Microencapsulation process
|
|
US4415732A
(en)
|
1981-03-27 |
1983-11-15 |
University Patents, Inc. |
Phosphoramidite compounds and processes
|
|
US4426330A
(en)
|
1981-07-20 |
1984-01-17 |
Lipid Specialties, Inc. |
Synthetic phospholipid compounds
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
JPS60100516A
(ja)
|
1983-11-04 |
1985-06-04 |
Takeda Chem Ind Ltd |
徐放型マイクロカプセルの製造法
|
|
US5700785A
(en)
|
1984-07-11 |
1997-12-23 |
Temple University - Of The Commonwealth System Of Higher Education |
3'-deoxy or 3'-O-substituted-2',5'-oligoadenylates as antiviral agents
|
|
US5643889A
(en)
|
1984-07-11 |
1997-07-01 |
Temple University-Of The Commonwealth System Of Pennsylvania |
Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
|
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
|
EP0260032B1
(en)
|
1986-09-08 |
1994-01-26 |
Ajinomoto Co., Inc. |
Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
|
|
US6005094A
(en)
|
1986-10-28 |
1999-12-21 |
Genta Incorporated |
Oligonucleotide analogues having improved stability at acid pH
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US4904582A
(en)
|
1987-06-11 |
1990-02-27 |
Synthetic Genetics |
Novel amphiphilic nucleic acid conjugates
|
|
US5188897A
(en)
|
1987-10-22 |
1993-02-23 |
Temple University Of The Commonwealth System Of Higher Education |
Encapsulated 2',5'-phosphorothioate oligoadenylates
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
US5525465A
(en)
|
1987-10-28 |
1996-06-11 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Oligonucleotide-polyamide conjugates and methods of production and applications of the same
|
|
DE3738460A1
(de)
|
1987-11-12 |
1989-05-24 |
Max Planck Gesellschaft |
Modifizierte oligonukleotide
|
|
WO1989005358A1
(en)
|
1987-11-30 |
1989-06-15 |
University Of Iowa Research Foundation |
Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
US5750666A
(en)
|
1988-05-26 |
1998-05-12 |
Competitve Technologies, Inc. |
Polynucleotide phosphorodithioate compounds
|
|
US5149782A
(en)
|
1988-08-19 |
1992-09-22 |
Tanox Biosystems, Inc. |
Molecular conjugates containing cell membrane-blending agents
|
|
US5512439A
(en)
|
1988-11-21 |
1996-04-30 |
Dynal As |
Oligonucleotide-linked magnetic particles and uses thereof
|
|
US5354844A
(en)
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
|
ATE133087T1
(de)
|
1989-05-04 |
1996-02-15 |
Southern Res Inst |
Einkapselungsverfahren
|
|
US5162115A
(en)
|
1989-05-09 |
1992-11-10 |
Pietronigro Dennis D |
Antineoplastic solution and method for treating neoplasms
|
|
US5051257A
(en)
|
1989-05-09 |
1991-09-24 |
Pietronigro Dennis D |
Antineoplastic solution and method for treating neoplasms
|
|
ZA902710B
(en)
|
1989-05-22 |
1991-12-24 |
Univ Georgia Res Found |
Enzyme luminescence assay
|
|
US5391723A
(en)
|
1989-05-31 |
1995-02-21 |
Neorx Corporation |
Oligonucleotide conjugates
|
|
US4958013A
(en)
|
1989-06-06 |
1990-09-18 |
Northwestern University |
Cholesteryl modified oligonucleotides
|
|
US5227170A
(en)
|
1989-06-22 |
1993-07-13 |
Vestar, Inc. |
Encapsulation process
|
|
JPH0383914A
(ja)
|
1989-08-18 |
1991-04-09 |
W R Grace & Co |
ドラッグキャリアー
|
|
US5591722A
(en)
|
1989-09-15 |
1997-01-07 |
Southern Research Institute |
2'-deoxy-4'-thioribonucleosides and their antiviral activity
|
|
US5527528A
(en)
|
1989-10-20 |
1996-06-18 |
Sequus Pharmaceuticals, Inc. |
Solid-tumor treatment method
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5356633A
(en)
|
1989-10-20 |
1994-10-18 |
Liposome Technology, Inc. |
Method of treatment of inflamed tissues
|
|
US5495009A
(en)
|
1989-10-24 |
1996-02-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs containing thioformacetal linkages
|
|
ATE190981T1
(de)
|
1989-10-24 |
2000-04-15 |
Isis Pharmaceuticals Inc |
2'-modifizierte nukleotide
|
|
US5264562A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences, Inc. |
Oligonucleotide analogs with novel linkages
|
|
US5177198A
(en)
|
1989-11-30 |
1993-01-05 |
University Of N.C. At Chapel Hill |
Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
|
|
US5469854A
(en)
|
1989-12-22 |
1995-11-28 |
Imarx Pharmaceutical Corp. |
Methods of preparing gas-filled liposomes
|
|
US5580575A
(en)
|
1989-12-22 |
1996-12-03 |
Imarx Pharmaceutical Corp. |
Therapeutic drug delivery systems
|
|
US5486603A
(en)
|
1990-01-08 |
1996-01-23 |
Gilead Sciences, Inc. |
Oligonucleotide having enhanced binding affinity
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US5646265A
(en)
*
|
1990-01-11 |
1997-07-08 |
Isis Pharmceuticals, Inc. |
Process for the preparation of 2'-O-alkyl purine phosphoramidites
|
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
|
WO1992003568A1
(en)
|
1990-08-13 |
1992-03-05 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5670633A
(en)
*
|
1990-01-11 |
1997-09-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
|
US6153737A
(en)
|
1990-01-11 |
2000-11-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
US5578718A
(en)
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
|
US5514786A
(en)
|
1990-01-11 |
1996-05-07 |
Isis Pharmaceuticals, Inc. |
Compositions for inhibiting RNA activity
|
|
US6358931B1
(en)
|
1990-01-11 |
2002-03-19 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating RNA
|
|
US6399754B1
(en)
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
|
US6395492B1
(en)
*
|
1990-01-11 |
2002-05-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
AU7579991A
(en)
|
1990-02-20 |
1991-09-18 |
Gilead Sciences, Inc. |
Pseudonucleosides and pseudonucleotides and their polymers
|
|
US5658731A
(en)
*
|
1990-04-09 |
1997-08-19 |
Europaisches Laboratorium Fur Molekularbiologie |
2'-O-alkylnucleotides as well as polymers which contain such nucleotides
|
|
US5470967A
(en)
|
1990-04-10 |
1995-11-28 |
The Dupont Merck Pharmaceutical Company |
Oligonucleotide analogs with sulfamate linkages
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
|
WO1991017424A1
(en)
|
1990-05-03 |
1991-11-14 |
Vical, Inc. |
Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
|
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5614617A
(en)
|
1990-07-27 |
1997-03-25 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
|
US5386023A
(en)
|
1990-07-27 |
1995-01-31 |
Isis Pharmaceuticals |
Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
|
|
US5688941A
(en)
|
1990-07-27 |
1997-11-18 |
Isis Pharmaceuticals, Inc. |
Methods of making conjugated 4' desmethyl nucleoside analog compounds
|
|
US6262241B1
(en)
|
1990-08-13 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Compound for detecting and modulating RNA activity and gene expression
|
|
WO1992003464A1
(en)
|
1990-08-28 |
1992-03-05 |
Microprobe Corporation |
Solid support synthesis of 3'-tailed oligonucleotides via a linking molecule
|
|
US5512667A
(en)
|
1990-08-28 |
1996-04-30 |
Reed; Michael W. |
Trifunctional intermediates for preparing 3'-tailed oligonucleotides
|
|
US5561225A
(en)
|
1990-09-19 |
1996-10-01 |
Southern Research Institute |
Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
|
|
AU662298B2
(en)
|
1990-09-20 |
1995-08-31 |
Gilead Sciences, Inc. |
Modified internucleoside linkages
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
AU643141B2
(en)
|
1991-03-15 |
1993-11-04 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
|
WO1994008003A1
(en)
|
1991-06-14 |
1994-04-14 |
Isis Pharmaceuticals, Inc. |
ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
|
|
JP3220180B2
(ja)
|
1991-05-23 |
2001-10-22 |
三菱化学株式会社 |
薬剤含有タンパク質結合リポソーム
|
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
|
DK51092D0
(da)
|
1991-05-24 |
1992-04-15 |
Ole Buchardt |
Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
|
|
US5770209A
(en)
*
|
1991-08-30 |
1998-06-23 |
University Of South Florida |
Acceleration of wound healing using connective tissue growth factor
|
|
US5214135A
(en)
|
1991-08-30 |
1993-05-25 |
Chemgenes Corporation |
N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides
|
|
US5525719A
(en)
|
1991-08-30 |
1996-06-11 |
Chemgenes Corporation |
N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
|
|
US7384634B2
(en)
*
|
1991-08-30 |
2008-06-10 |
University Of South Florida |
Connective tissue growth factor
|
|
NZ244306A
(en)
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
|
US5607923A
(en)
|
1991-10-15 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
|
|
US5599797A
(en)
|
1991-10-15 |
1997-02-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
TW393513B
(en)
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
|
US5359044A
(en)
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
|
US5856455A
(en)
|
1991-12-24 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Gapped 2'-modified oligonucleotides
|
|
IL104461A
(en)
|
1992-01-22 |
2001-05-20 |
Hoechst Ag |
Oligonucleotide analogs, their preparation and pharmaceutical compositions containing them
|
|
US6113946A
(en)
|
1992-04-03 |
2000-09-05 |
The Regents Of The University Of California |
Self-assembling polynucleotide delivery system comprising dendrimer polycations
|
|
US5633360A
(en)
|
1992-04-14 |
1997-05-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs capable of passive cell membrane permeation
|
|
US5817781A
(en)
|
1992-06-01 |
1998-10-06 |
Gilead Sciences, Inc. |
Modified internucleoside linkages (II)
|
|
EP0577558A2
(de)
|
1992-07-01 |
1994-01-05 |
Ciba-Geigy Ag |
Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
|
|
US6172208B1
(en)
|
1992-07-06 |
2001-01-09 |
Genzyme Corporation |
Oligonucleotides modified with conjugate groups
|
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
|
US5583020A
(en)
|
1992-11-24 |
1996-12-10 |
Ribozyme Pharmaceuticals, Inc. |
Permeability enhancers for negatively charged polynucleotides
|
|
US5574142A
(en)
|
1992-12-15 |
1996-11-12 |
Microprobe Corporation |
Peptide linkers for improved oligonucleotide delivery
|
|
JP3351476B2
(ja)
|
1993-01-22 |
2002-11-25 |
三菱化学株式会社 |
リン脂質誘導体及びそれを含有するリポソーム
|
|
US5395619A
(en)
|
1993-03-03 |
1995-03-07 |
Liposome Technology, Inc. |
Lipid-polymer conjugates and liposomes
|
|
CN1124980A
(zh)
|
1993-03-31 |
1996-06-19 |
海布里顿公司 |
具有改良抗流感活性的经修饰寡核苷酸
|
|
ATE160572T1
(de)
|
1993-03-31 |
1997-12-15 |
Sanofi Sa |
Oligonucleotide mit amidverkettungen die phosphoesterverkettungen einsetzen
|
|
FR2705099B1
(fr)
|
1993-05-12 |
1995-08-04 |
Centre Nat Rech Scient |
Oligonucléotides phosphorothioates triesters et procédé de préparation.
|
|
EP0626387B1
(de)
|
1993-05-12 |
1999-03-10 |
Novartis AG |
Nukleoside und Oligonukleotide mit 2'-Ethergruppen
|
|
US6015886A
(en)
|
1993-05-24 |
2000-01-18 |
Chemgenes Corporation |
Oligonucleotide phosphate esters
|
|
US5428149A
(en)
|
1993-06-14 |
1995-06-27 |
Washington State University Research Foundation |
Method for palladium catalyzed carbon-carbon coulping and products
|
|
US5580972A
(en)
|
1993-06-14 |
1996-12-03 |
Nexstar Pharmaceuticals, Inc. |
Purine nucleoside modifications by palladium catalyzed methods
|
|
US5534259A
(en)
|
1993-07-08 |
1996-07-09 |
Liposome Technology, Inc. |
Polymer compound and coated particle composition
|
|
US5532130A
(en)
|
1993-07-20 |
1996-07-02 |
Dyad Pharmaceutical Corporation |
Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
|
|
US5543158A
(en)
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
|
US5614621A
(en)
|
1993-07-29 |
1997-03-25 |
Isis Pharmaceuticals, Inc. |
Process for preparing oligonucleotides using silyl-containing diamino phosphorous reagents
|
|
US5417978A
(en)
|
1993-07-29 |
1995-05-23 |
Board Of Regents, The University Of Texas System |
Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
|
|
US5808036A
(en)
|
1993-09-01 |
1998-09-15 |
Research Corporation Technologies Inc. |
Stem-loop oligonucleotides containing parallel and antiparallel binding domains
|
|
DE69431669T2
(de)
|
1993-09-02 |
2003-10-23 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
|
|
DE69433036T2
(de)
|
1993-09-03 |
2004-05-27 |
Isis Pharmaceuticals, Inc., Carlsbad |
Aminoderivatisierte nukleoside und oligonukleoside
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
GB9320782D0
(en)
|
1993-10-08 |
1993-12-01 |
Univ Leeds Innovations Ltd |
Stabilising of proteins on solution
|
|
DE69415343T2
(de)
|
1993-10-27 |
1999-08-26 |
Ribozyme Pharmaceuticals |
2'-amido-und 2'-peptido-modifizierte oligonukleotide
|
|
US6060456A
(en)
|
1993-11-16 |
2000-05-09 |
Genta Incorporated |
Chimeric oligonucleoside compounds
|
|
AU687492B2
(en)
|
1993-11-16 |
1998-02-26 |
Genta Incorporated |
Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphonate internucleosidyl linkages
|
|
DE69434617D1
(de)
|
1993-11-19 |
2006-04-06 |
Univ Sydney |
Verfahren zur prophylaxe oder kontrolle des katarakts
|
|
AU687508B2
(en)
|
1993-12-17 |
1998-02-26 |
Ohio State University, The |
Antisense oligonucleotides to suppress eicosanoid formation
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
JPH09509181A
(ja)
|
1994-02-18 |
1997-09-16 |
ハイブリドン，インコーポレーテッド |
抗呼吸器合胞体ウイルス活性を有するオリゴヌクレオチド
|
|
US5539083A
(en)
|
1994-02-23 |
1996-07-23 |
Isis Pharmaceuticals, Inc. |
Peptide nucleic acid combinatorial libraries and improved methods of synthesis
|
|
US5646126A
(en)
|
1994-02-28 |
1997-07-08 |
Epoch Pharmaceuticals |
Sterol modified oligonucleotide duplexes having anticancer activity
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5651981A
(en)
|
1994-03-29 |
1997-07-29 |
Northwestern University |
Cationic phospholipids for transfection
|
|
US5625050A
(en)
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
|
US5451569A
(en)
|
1994-04-19 |
1995-09-19 |
Hong Kong University Of Science And Technology R & D Corporation Limited |
Pulmonary drug delivery system
|
|
US5543152A
(en)
|
1994-06-20 |
1996-08-06 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
|
US5777153A
(en)
|
1994-07-08 |
1998-07-07 |
Gilead Sciences, Inc. |
Cationic lipids
|
|
US5580731A
(en)
|
1994-08-25 |
1996-12-03 |
Chiron Corporation |
N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
|
|
US5837533A
(en)
|
1994-09-28 |
1998-11-17 |
American Home Products Corporation |
Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
|
|
US5591721A
(en)
*
|
1994-10-25 |
1997-01-07 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
US5681940A
(en)
|
1994-11-02 |
1997-10-28 |
Icn Pharmaceuticals |
Sugar modified nucleosides and oligonucleotides
|
|
US5512295A
(en)
|
1994-11-10 |
1996-04-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synthetic liposomes for enhanced uptake and delivery
|
|
US5948767A
(en)
|
1994-12-09 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphile/DNA complexes
|
|
US5767099A
(en)
|
1994-12-09 |
1998-06-16 |
Genzyme Corporation |
Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
|
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
|
AUPN166195A0
(en)
|
1995-03-13 |
1995-04-06 |
Norvet Research Pty Limited |
Process for glucan extraction
|
|
US5674683A
(en)
|
1995-03-21 |
1997-10-07 |
Research Corporation Technologies, Inc. |
Stem-loop and circular oligonucleotides and method of using
|
|
WO1996033761A1
(en)
|
1995-04-28 |
1996-10-31 |
Medtronic, Inc. |
Intraparenchymal infusion catheter system
|
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
|
ATE285477T1
(de)
|
1995-06-07 |
2005-01-15 |
Inex Pharmaceutical Corp |
Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
|
|
US6221911B1
(en)
|
1995-06-07 |
2001-04-24 |
Karo Bio Ab |
Uses for thyroid hormone compounds or thyroid hormone-like compounds
|
|
US5851548A
(en)
|
1995-06-07 |
1998-12-22 |
Gen-Probe Incorporated |
Liposomes containing cationic lipids and vitamin D
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
EP0874910A4
(en)
|
1995-06-07 |
1999-04-21 |
Life Technologies Inc |
ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
|
|
US5672662A
(en)
|
1995-07-07 |
1997-09-30 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
|
|
WO1997014709A1
(en)
|
1995-10-13 |
1997-04-24 |
F. Hoffmann-La Roche Ag |
Antisense oligomers
|
|
US5734041A
(en)
|
1995-10-20 |
1998-03-31 |
Mcgill University |
Preparation of chiral phosphorothioate oligomers
|
|
US5705621A
(en)
|
1995-11-17 |
1998-01-06 |
Isis Pharmaceuticals, Inc. |
Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same
|
|
US6344436B1
(en)
|
1996-01-08 |
2002-02-05 |
Baylor College Of Medicine |
Lipophilic peptides for macromolecule delivery
|
|
US5684143A
(en)
|
1996-02-21 |
1997-11-04 |
Lynx Therapeutics, Inc. |
Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
|
|
US6331617B1
(en)
|
1996-03-21 |
2001-12-18 |
University Of Iowa Research Foundation |
Positively charged oligonucleotides as regulators of gene expression
|
|
US6299895B1
(en)
|
1997-03-24 |
2001-10-09 |
Neurotech S.A. |
Device and method for treating ophthalmic diseases
|
|
US6444806B1
(en)
|
1996-04-30 |
2002-09-03 |
Hisamitsu Pharmaceutical Co., Inc. |
Conjugates and methods of forming conjugates of oligonucleotides and carbohydrates
|
|
US5735814A
(en)
|
1996-04-30 |
1998-04-07 |
Medtronic, Inc. |
Techniques of treating neurodegenerative disorders by brain infusion
|
|
WO2005121370A2
(en)
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds that facilitate risc loading
|
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6506564B1
(en)
|
1996-07-29 |
2003-01-14 |
Nanosphere, Inc. |
Nanoparticles having oligonucleotides attached thereto and uses therefor
|
|
US5789416B1
(en)
|
1996-08-27 |
1999-10-05 |
Cv Therapeutics Inc |
N6 mono heterocyclic substituted adenosine derivatives
|
|
US6111085A
(en)
|
1996-09-13 |
2000-08-29 |
Isis Pharmaceuticals, Inc. |
Carbamate-derivatized nucleosides and oligonucleosides
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
US6977244B2
(en)
*
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
FR2755976B1
(fr)
|
1996-11-15 |
1999-01-15 |
Idm Immuno Designed Molecules |
Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
|
|
US6248878B1
(en)
|
1996-12-24 |
2001-06-19 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside analogs
|
|
US7789841B2
(en)
|
1997-02-06 |
2010-09-07 |
Exogen, Inc. |
Method and apparatus for connective tissue treatment
|
|
US5955594A
(en)
|
1997-04-30 |
1999-09-21 |
Mishra; Lopa |
Nucleic acids encoding proteins for early liver development
|
|
DE69841002D1
(de)
|
1997-05-14 |
2009-09-03 |
Univ British Columbia |
Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
|
|
AU731909B2
(en)
|
1997-07-01 |
2001-04-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
|
US6025140A
(en)
|
1997-07-24 |
2000-02-15 |
Perseptive Biosystems, Inc. |
Membrane-permeable constructs for transport across a lipid membrane
|
|
BR9813202B1
(pt)
|
1997-09-15 |
2011-11-01 |
|
complexo de administração de genes; processo de transdução de células com material genético estranho, composição útil para administração de material genético e uso de um complexo de administração de genes.
|
|
US6028183A
(en)
|
1997-11-07 |
2000-02-22 |
Gilead Sciences, Inc. |
Pyrimidine derivatives and oligonucleotides containing same
|
|
ATE401312T1
(de)
|
1997-12-15 |
2008-08-15 |
Astellas Pharma Inc |
Pyrimidin-5-carboxamid-derivate
|
|
US6506559B1
(en)
*
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
US6562618B1
(en)
*
|
1997-12-25 |
2003-05-13 |
Japan Tobacco, Inc. |
Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
|
|
US6020475A
(en)
|
1998-02-10 |
2000-02-01 |
Isis Pharmeuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
|
EP1071753A2
(en)
|
1998-04-20 |
2001-01-31 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
|
AU745880B2
(en)
|
1998-05-21 |
2002-04-11 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
|
US20040241845A1
(en)
|
1998-05-22 |
2004-12-02 |
Luc Desgroseillers |
Mammalian staufen and use thereof
|
|
US6096875A
(en)
|
1998-05-29 |
2000-08-01 |
The Perlein-Elmer Corporation |
Nucleotide compounds including a rigid linker
|
|
US6300319B1
(en)
|
1998-06-16 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Targeted oligonucleotide conjugates
|
|
US6277967B1
(en)
|
1998-07-14 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
|
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
|
EP1096921B1
(en)
|
1998-07-20 |
2003-04-16 |
Protiva Biotherapeutics Inc. |
Liposomal encapsulated nucleic acid-complexes
|
|
US6271358B1
(en)
|
1998-07-27 |
2001-08-07 |
Isis Pharmaceuticals, Inc. |
RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
|
|
US6378526B1
(en)
|
1998-08-03 |
2002-04-30 |
Insite Vision, Incorporated |
Methods of ophthalmic administration
|
|
US6043352A
(en)
|
1998-08-07 |
2000-03-28 |
Isis Pharmaceuticals, Inc. |
2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
|
|
US20040009938A1
(en)
|
1998-08-07 |
2004-01-15 |
Muthiah Manoharan |
Methods of enhancing renal uptake of oligonucleotides
|
|
US6335437B1
(en)
|
1998-09-07 |
2002-01-01 |
Isis Pharmaceuticals, Inc. |
Methods for the preparation of conjugated oligomers
|
|
US6344323B1
(en)
|
1998-09-16 |
2002-02-05 |
Vitagenix, Inc. |
Compositions and methods for inhibiting cox-2 expression and treating cox-2 associated disorders by using cox-2 antisense oligonucleotides
|
|
US6020483A
(en)
|
1998-09-25 |
2000-02-01 |
Nexstar Pharmaceuticals, Inc. |
Nucleoside modifications by palladium catalyzed methods
|
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
|
US6475490B1
(en)
|
1998-10-19 |
2002-11-05 |
Fordham University |
Compositions and methods for promoting tissue repair using heat shock proteins
|
|
US6328765B1
(en)
|
1998-12-03 |
2001-12-11 |
Gore Enterprise Holdings, Inc. |
Methods and articles for regenerating living tissue
|
|
US7115390B1
(en)
|
1998-12-14 |
2006-10-03 |
Fibrogen, Inc. |
Connective tissue growth factor fragments and methods and uses thereof
|
|
AU775391B2
(en)
*
|
1998-12-14 |
2004-07-29 |
Fibrogen, Inc. |
Connective tissue growth factor fragments and methods and uses thereof
|
|
US6455586B1
(en)
|
1998-12-15 |
2002-09-24 |
Leonard L. Kaplan |
Topical immunomodulating compositions for treatment of aids, Hepatitis B & C, other infectious diseases, and cancer
|
|
EP1621212B1
(en)
|
1999-01-27 |
2011-11-16 |
Coda Therapeutics, Inc. |
Formulations comprising antisense nucleotides to connexins
|
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
US6465628B1
(en)
|
1999-02-04 |
2002-10-15 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
|
US6207819B1
(en)
|
1999-02-12 |
2001-03-27 |
Isis Pharmaceuticals, Inc. |
Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
|
|
ATE287897T2
(de)
|
1999-02-12 |
2005-02-15 |
Sankyo Co |
Analoga von nukleosiden und oligonukleotiden
|
|
EP1156812A4
(en)
|
1999-02-23 |
2004-09-29 |
Isis Pharmaceuticals Inc |
MULTIPARTICULAR FORMULATION
|
|
US6121437A
(en)
|
1999-03-16 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Phosphate and thiophosphate protecting groups
|
|
US20020049173A1
(en)
|
1999-03-26 |
2002-04-25 |
Bennett C. Frank |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
|
US6706491B1
(en)
*
|
1999-04-09 |
2004-03-16 |
The Board Of Trustees Of The University Of Illinois |
Reagents and methods for identifying and modulating expression of genes regulated by p21
|
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
|
US6033910A
(en)
|
1999-07-19 |
2000-03-07 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of MAP kinase kinase 6 expression
|
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
|
US6331313B1
(en)
|
1999-10-22 |
2001-12-18 |
Oculex Pharmaceticals, Inc. |
Controlled-release biocompatible ocular drug delivery implant devices and methods
|
|
GB9925459D0
(en)
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
|
JP2001206899A
(ja)
|
1999-11-18 |
2001-07-31 |
Japan Tobacco Inc |
ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
|
|
US20040072785A1
(en)
|
1999-11-23 |
2004-04-15 |
Wolff Jon A. |
Intravascular delivery of non-viral nucleic acid
|
|
DE10160151A1
(de)
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
US7098030B2
(en)
|
1999-12-31 |
2006-08-29 |
Mirus Bio Corporation |
Polyampholytes for delivering polyions to a cell
|
|
WO2005019453A2
(en)
|
2001-05-18 |
2005-03-03 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US20050032733A1
(en)
*
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
|
CA2403397A1
(en)
|
2000-03-16 |
2001-09-20 |
Genetica, Inc. |
Methods and compositions for rna interference
|
|
DK2796553T3
(da)
*
|
2000-03-30 |
2019-09-30 |
Whitehead Inst Biomedical Res |
Rna-sekvensspecifikke formidlere af rna-interferens
|
|
US7108721B2
(en)
|
2000-05-11 |
2006-09-19 |
Massachusetts Institute Of Technology |
Tissue regrafting
|
|
US7175844B2
(en)
*
|
2000-07-18 |
2007-02-13 |
Joslin Diabetes Center, Inc. |
Methods of modulating fibrosis
|
|
JP5154728B2
(ja)
|
2000-07-24 |
2013-02-27 |
クレニツキー・ファーマシューティカルズ，インコーポレイテッド |
神経栄養活性を有する置換５−アルキニルピリミジン
|
|
US6346416B1
(en)
|
2000-08-29 |
2002-02-12 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of HPK/GCK-like kinase expression
|
|
US6559279B1
(en)
|
2000-09-08 |
2003-05-06 |
Isis Pharmaceuticals, Inc. |
Process for preparing peptide derivatized oligomeric compounds
|
|
US6794137B2
(en)
|
2000-09-08 |
2004-09-21 |
New York University |
Gene markers useful for detecting skin damage in response to ultraviolet radiation
|
|
US6753321B2
(en)
*
|
2000-09-15 |
2004-06-22 |
Genvec, Inc. |
Method of modulating neovascularization
|
|
US20020081736A1
(en)
|
2000-11-03 |
2002-06-27 |
Conroy Susan E. |
Nucleic acid delivery
|
|
US20020132788A1
(en)
|
2000-11-06 |
2002-09-19 |
David Lewis |
Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
|
|
CZ302719B6
(cs)
|
2000-12-01 |
2011-09-21 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
|
|
FR2818642B1
(fr)
|
2000-12-26 |
2005-07-15 |
Hoechst Marion Roussel Inc |
Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
|
|
EP1354038A2
(en)
|
2000-12-28 |
2003-10-22 |
J & J Research Pty Ltd |
Double-stranded rna-mediated gene suppression
|
|
DE10100127A1
(de)
|
2001-01-03 |
2002-10-02 |
Henkel Kgaa |
Verfahren zur Bestimmung der Homeostase der Haut
|
|
US7507724B2
(en)
|
2001-01-16 |
2009-03-24 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
|
US7906492B2
(en)
|
2001-01-16 |
2011-03-15 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
|
US7044945B2
(en)
*
|
2001-03-30 |
2006-05-16 |
Sand Bruce J |
Prevention of regression in thermal ciliary muscle tendinoplasty
|
|
WO2002087541A1
(en)
|
2001-04-30 |
2002-11-07 |
Protiva Biotherapeutics Inc. |
Lipid-based formulations for gene transfer
|
|
GB0111279D0
(en)
*
|
2001-05-10 |
2001-06-27 |
Nycomed Imaging As |
Radiolabelled liposomes
|
|
US20050239731A1
(en)
|
2001-05-18 |
2005-10-27 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA)
|
|
US20070173473A1
(en)
|
2001-05-18 |
2007-07-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
|
|
US20070032441A1
(en)
|
2001-05-18 |
2007-02-08 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
|
|
WO2003070884A2
(en)
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
CA2451643C
(en)
|
2001-06-21 |
2012-11-13 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
|
US20050019915A1
(en)
|
2001-06-21 |
2005-01-27 |
Bennett C. Frank |
Antisense modulation of superoxide dismutase 1, soluble expression
|
|
DE10131458A1
(de)
*
|
2001-06-29 |
2003-01-09 |
Aventis Pharma Gmbh |
Verfahren zur Identifizierung von Verbindungen zur Therapie von Alterungsprozessen des Herz-Kreislauf Systems
|
|
US20030158403A1
(en)
*
|
2001-07-03 |
2003-08-21 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant chimeric oligonucleotides
|
|
DE10133858A1
(de)
|
2001-07-12 |
2003-02-06 |
Aventis Pharma Gmbh |
Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
|
|
WO2003012052A2
(en)
|
2001-07-30 |
2003-02-13 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Specific inhibition of gene expression by small double stranded rnas
|
|
WO2003024308A2
(en)
*
|
2001-09-18 |
2003-03-27 |
Fibrogen, Inc. |
Methods of assaying connective tissue growth factor
|
|
EP1438413A4
(en)
*
|
2001-10-03 |
2006-06-07 |
Selective Genetics Inc |
CROSSING OF NUCLEIC ACID MOLECULES IN A FLUID SPACE AND EXPRESSION IN REPAIR CELLS
|
|
WO2003035876A1
(de)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus
|
|
WO2003035083A1
(de)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
EP2325193A3
(en)
|
2001-11-02 |
2012-05-02 |
Insert Therapeutics, Inc. |
Methods and compositions for therapeutic use of RNA interference
|
|
US6965025B2
(en)
*
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
|
ATE526041T1
(de)
|
2001-12-11 |
2011-10-15 |
Fibrogen Inc |
Verfahren zur hemmung okularer vorgänge
|
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
|
MXPA04007403A
(es)
*
|
2002-02-01 |
2005-07-01 |
Univ Mcgill |
Oligonucleotidos que comprenden segmentos alternos y usos de los mismos.
|
|
EP2455467B1
(en)
|
2002-02-01 |
2016-10-05 |
Life Technologies Corporation |
Double-stranded oligonucleotides
|
|
EP1572902B1
(en)
|
2002-02-01 |
2014-06-11 |
Life Technologies Corporation |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
|
US6923833B2
(en)
|
2002-04-09 |
2005-08-02 |
Ray C. Wasielewski |
Biologically reabsorbable acetabular constraining components and materials for use with a hip replacement prosthesis and bioreabsorbable materials to augment hip replacement stability and function
|
|
EP1495120B1
(en)
|
2002-04-18 |
2012-10-10 |
Acuity Pharmaceuticals, Inc |
Means and methods for the specific modulation of target genes in the eye
|
|
WO2003099840A1
(en)
*
|
2002-05-24 |
2003-12-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
|
FR2840217B1
(fr)
|
2002-06-03 |
2005-06-24 |
Oreal |
Compositions cosmetiques comprenant au moins un oligonucleotide d'arn double brin (dsrna)et leurs utilisations
|
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
|
DK1527176T4
(en)
|
2002-08-05 |
2017-07-03 |
Silence Therapeutics Gmbh |
ADDITIONAL NEW FORMS OF INTERFERRING RNA MOLECULES
|
|
DE10238298A1
(de)
|
2002-08-21 |
2004-03-04 |
Beiersdorf Ag |
Verwendung von Antisense-Oligonucleotiden zur Behandlung von degenerativen Hauterscheinungen
|
|
US20040137471A1
(en)
*
|
2002-09-18 |
2004-07-15 |
Timothy Vickers |
Efficient reduction of target RNA's by single-and double-stranded oligomeric compounds
|
|
ATE513843T1
(de)
|
2002-09-25 |
2011-07-15 |
Univ Massachusetts |
Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna
|
|
EP1658304A4
(en)
|
2002-09-28 |
2009-01-14 |
Massachusetts Inst Technology |
THERAPY ANTIGRIPPALE
|
|
US20060035344A1
(en)
|
2002-10-18 |
2006-02-16 |
Pachuk Catherine J |
Double-stranded rna structures and constructs, and methods for generating and using the same
|
|
US7309361B2
(en)
|
2002-10-23 |
2007-12-18 |
Wasielewski Ray C |
Biologic modular tibial and femoral component augments for use with total knee arthroplasty
|
|
EP1575574A4
(en)
|
2002-10-30 |
2007-11-07 |
Blood Res Center |
METHOD FOR TREATING AND PREVENTING APOPTOSIS-BASED DISEASES BY MEANS OF RNA INTERFERENCE AGENTS
|
|
CA2504926C
(en)
|
2002-11-01 |
2014-01-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for sirna inhibition of hif-1 alpha
|
|
US20040192629A1
(en)
|
2002-11-04 |
2004-09-30 |
University Of Massachusetts |
Allele-specific RNA interference
|
|
US7892793B2
(en)
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
EP1560931B1
(en)
|
2002-11-14 |
2011-07-27 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
|
DE10254214A1
(de)
|
2002-11-20 |
2004-06-09 |
Beiersdorf Ag |
Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz
|
|
ES2343318T3
(es)
|
2002-11-26 |
2010-07-28 |
University Of Massachusetts |
Administracion de arnsis.
|
|
WO2004065600A2
(en)
|
2003-01-17 |
2004-08-05 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Rna interference by palindromic or modified rna molecules
|
|
DE10302421A1
(de)
|
2003-01-21 |
2004-07-29 |
Ribopharma Ag |
Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
|
|
EP1606301A4
(en)
|
2003-01-21 |
2006-06-14 |
Archemix Corp |
APTAMERIC THERAPEUTICS FOR MEDICINAL THERAPY FOR EYES
|
|
CA2514912A1
(en)
|
2003-02-05 |
2004-08-26 |
University Of Massachusetts |
Rnai targeting of viruses
|
|
CN1768139A
(zh)
*
|
2003-02-10 |
2006-05-03 |
独立行政法人产业技术总合研究所 |
通过dna干扰调控基因的表达
|
|
US20040162235A1
(en)
|
2003-02-18 |
2004-08-19 |
Trubetskoy Vladimir S. |
Delivery of siRNA to cells using polyampholytes
|
|
US20040167090A1
(en)
|
2003-02-21 |
2004-08-26 |
Monahan Sean D. |
Covalent modification of RNA for in vitro and in vivo delivery
|
|
WO2004078950A2
(en)
|
2003-03-05 |
2004-09-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
METHODS AND COMPOSITIONS FOR SELECTIVE RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMAL CELLS
|
|
US6962331B2
(en)
|
2003-03-06 |
2005-11-08 |
Canon Kabushiki Kaisha |
Sheet stacking apparatus
|
|
EP2216407B1
(en)
|
2003-03-07 |
2016-01-13 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
|
EP1608733B1
(en)
|
2003-04-02 |
2011-12-07 |
Dharmacon, Inc. |
Modified polynucleotides for use in rna interference
|
|
AU2004233092C9
(en)
|
2003-04-17 |
2010-10-28 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
|
US7462602B2
(en)
|
2003-05-01 |
2008-12-09 |
University Of Florida Research Foundation, Inc. |
Anti-scarring ribozymes and methods
|
|
EP2251039A3
(en)
*
|
2003-05-30 |
2010-12-08 |
Nippon Shinyaku Co., Ltd. |
Oligo double-stranded rna inhibiting the expression of bcl-2 and pharmaceutical composition containing the same
|
|
US20060178327A1
(en)
|
2003-05-30 |
2006-08-10 |
Yeung Wah Hin A |
Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro
|
|
AU2004252442B2
(en)
|
2003-06-02 |
2010-04-08 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of FNAi
|
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
US7405274B2
(en)
*
|
2003-06-04 |
2008-07-29 |
Fibrogen, Inc. |
Connective tissue growth factor antibodies
|
|
ES2761262T3
(es)
*
|
2003-06-13 |
2020-05-19 |
Alnylam Europe Ag |
Acido ribonucleico bicatenario con elevada eficacia en un organismo
|
|
US20050026823A1
(en)
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
|
ES2559828T3
(es)
|
2003-07-16 |
2016-02-16 |
Protiva Biotherapeutics Inc. |
ARN de interferencia encapsulado en lípidos
|
|
US20050106594A1
(en)
*
|
2003-08-22 |
2005-05-19 |
Andrew Ellington |
In vitro selection of aptamer beacons
|
|
WO2005024033A2
(en)
|
2003-09-11 |
2005-03-17 |
Universitätsklinikum Schleswig-Holstein Campus Lübeck |
Nucleotide sequences promoting the trans-membrane transport of nucleic acids
|
|
AU2004272646B2
(en)
|
2003-09-15 |
2011-11-24 |
Arbutus Biopharma Corporation |
Polyethyleneglycol-modified lipid compounds and uses thereof
|
|
WO2005038013A1
(en)
|
2003-10-07 |
2005-04-28 |
Isis Pharmaceuticals, Inc. |
Artisense oligonucleotides optimized for kidney targeting
|
|
EP1692154A4
(en)
|
2003-11-24 |
2009-07-08 |
Canji Inc |
REDUCTION OF SKIN TEMPERING
|
|
KR20180037067A
(ko)
|
2003-12-03 |
2018-04-10 |
코다 테라퓨틱스 (엔지) 리미티드 |
코넥신에 표적화된 안티센스 화합물 및 그의 사용 방법
|
|
US20080254487A1
(en)
|
2004-01-16 |
2008-10-16 |
Fibrogen, Inc. |
Connective Tissue Growth Factor Signaling
|
|
EP1718747B1
(en)
|
2004-02-06 |
2009-10-28 |
Dharmacon, Inc. |
Stabilized rnas as transfection controls and silencing reagents
|
|
WO2005078096A2
(en)
|
2004-02-09 |
2005-08-25 |
University Of Massachusetts |
Dual functional oligonucleotides for use in repressing mutant gene expression
|
|
US20060069050A1
(en)
|
2004-02-17 |
2006-03-30 |
University Of Massachusetts |
Methods and compositions for mediating gene silencing
|
|
US20080071068A1
(en)
|
2004-02-20 |
2008-03-20 |
Hideki Oba |
Cytoplasmic Localization Dna and Rna
|
|
EP1737956A2
(en)
|
2004-03-01 |
2007-01-03 |
Massachusetts Institute of Technology |
Rnai-based therapeutics for allergic rhinitis and asthma
|
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
|
WO2005098041A2
(en)
|
2004-03-26 |
2005-10-20 |
University Of Florida Research Foundation, Inc. |
Detection and treatment of fibrotic disorders
|
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
US7498316B2
(en)
|
2004-04-06 |
2009-03-03 |
University Of Massachusetts |
Methods and compositions for treating gain-of-function disorders using RNA interference
|
|
US20050265957A1
(en)
|
2004-04-08 |
2005-12-01 |
Monahan Sean D |
Polymerized formamides for use in delivery of compounds to cells
|
|
MXPA06012076A
(es)
*
|
2004-04-20 |
2007-01-25 |
Nastech Pharm Co |
Metodos y composiciones para mejorar el suministro de arn bicatenario o un acido nucleico hibrido bicatenario para regular la expresion genetica en celulas de mamifero.
|
|
US8168600B2
(en)
|
2004-04-23 |
2012-05-01 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for topical delivery of oligonucleotides
|
|
CA2566519C
(en)
|
2004-05-14 |
2020-04-21 |
Rosetta Genomics Ltd. |
Micrornas and uses thereof
|
|
WO2005113128A1
(en)
|
2004-05-20 |
2005-12-01 |
Eden Research Plc |
Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them
|
|
EP1766035B1
(en)
|
2004-06-07 |
2011-12-07 |
Protiva Biotherapeutics Inc. |
Lipid encapsulated interfering rna
|
|
US7740861B2
(en)
|
2004-06-16 |
2010-06-22 |
University Of Massachusetts |
Drug delivery product and methods
|
|
EP2292757A3
(en)
|
2004-08-23 |
2011-11-16 |
Sylentis S.A.U. |
Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs
|
|
US20060211766A1
(en)
|
2004-09-30 |
2006-09-21 |
Kaplan Leonard L |
Gelled immunomodulating topical compositions and a method of treating warts and other human papilloma virus skin infections
|
|
EP1796732B1
(en)
*
|
2004-10-01 |
2013-10-30 |
Novartis Vaccines and Diagnostics, Inc. |
Modified small interfering rna molecules and methods of use
|
|
US20100069620A1
(en)
|
2004-12-02 |
2010-03-18 |
Rxi Pharmaceuticals Corp. |
Novel compositions of chemically modified small interfering rna
|
|
AU2005311684A1
(en)
*
|
2004-12-02 |
2006-06-08 |
University Of Massachusetts |
Glucose-transport related genes, polypeptides, and methods of use thereof
|
|
US7910561B2
(en)
|
2004-12-15 |
2011-03-22 |
Merck Sharp & Dohme Corp. |
Inhibitors of Akt activity
|
|
WO2006066203A2
(en)
|
2004-12-16 |
2006-06-22 |
Alsgen, Llc |
Small interfering rna (sirna) molecules for modulating superoxide dismutase (sod)
|
|
US20060142228A1
(en)
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
|
TWI386225B
(zh)
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
|
|
US20060171943A1
(en)
|
2005-02-01 |
2006-08-03 |
Amgen Inc. |
Compositions and methods of treating fibrotic disorders
|
|
JP2008536874A
(ja)
*
|
2005-04-15 |
2008-09-11 |
ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム |
中性脂質組成物によるｓｉＲＮＡの送達
|
|
EP1891217A2
(en)
|
2005-05-27 |
2008-02-27 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of stromal cell-derived factor-1 (sdf-1) gene expression using short interfering nucleic acid (sina)
|
|
US20090220583A1
(en)
|
2005-06-09 |
2009-09-03 |
Lena Pereswetoff-Morath |
Method and composition for treating inflammatory disorders
|
|
AU2006280600B2
(en)
|
2005-08-17 |
2012-01-19 |
Bioneer Corporation |
Sirna-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
|
|
US20070161591A1
(en)
|
2005-08-18 |
2007-07-12 |
University Of Massachusetts |
Methods and compositions for treating neurological disease
|
|
US20090018097A1
(en)
|
2005-09-02 |
2009-01-15 |
Mdrna, Inc |
Modification of double-stranded ribonucleic acid molecules
|
|
EP1948245B1
(en)
|
2005-10-24 |
2011-10-05 |
University of Massachusetts |
Compositions and their uses for gene therapy of bone conditions
|
|
FR2894582B1
(fr)
|
2005-12-12 |
2008-02-22 |
Fabre Pierre Dermo Cosmetique |
Sirna anti myosine va et depigmentation de la peau
|
|
JP2009519033A
(ja)
|
2005-12-16 |
2009-05-14 |
ディアト |
核酸を細胞に送達するための細胞貫通ペプチド結合体
|
|
EP1976986A2
(en)
*
|
2005-12-30 |
2008-10-08 |
Intradigm Corporation |
Sirna compositions promoting scar-free wound healing of skin and methods for wound treatment
|
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
|
US20070231392A1
(en)
|
2006-01-23 |
2007-10-04 |
Ernst Wagner |
CHEMICALLY MODIFIED POLYCATION POLYMER FOR siRNA DELIVERY
|
|
AU2007210034A1
(en)
*
|
2006-01-26 |
2007-08-09 |
University Of Massachusetts |
RNA silencing agents for use in therapy and nanotransporters for efficient delivery of same
|
|
DK2002004T3
(en)
|
2006-03-23 |
2015-11-30 |
Roche Innovation Ct Copenhagen As |
LITTLE INTERNAL SEGMENTED INTERFERENCE RNA
|
|
PL2666859T3
(pl)
|
2006-04-03 |
2019-09-30 |
Roche Innovation Center Copenhagen A/S |
Kompozycja farmaceutyczna zawierająca antysensowne oligonukleotydy anty-miRNA
|
|
EP2505646A1
(en)
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of CRP
|
|
WO2007134161A2
(en)
|
2006-05-11 |
2007-11-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the pcsk9 gene
|
|
ES2390499T3
(es)
|
2006-06-12 |
2012-11-13 |
Opko Pharmaceuticals, Llc |
Composiciones y métodos para la inhibición de la angiogénesis por sirna
|
|
EP2712618B1
(en)
|
2006-06-23 |
2016-10-19 |
EnGeneIC Molecular Delivery Pty Ltd. |
Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
|
|
US20080039415A1
(en)
|
2006-08-11 |
2008-02-14 |
Gregory Robert Stewart |
Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
|
|
CN101500548A
(zh)
|
2006-08-18 |
2009-08-05 |
弗·哈夫曼-拉罗切有限公司 |
用于体内递送多核苷酸的多缀合物
|
|
AU2007299705B2
(en)
*
|
2006-09-22 |
2012-09-06 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
|
|
US20080193443A1
(en)
*
|
2006-10-30 |
2008-08-14 |
Oxana Beskrovnaya |
Methods and compositions for the treatment of polycystic diseases
|
|
US8039010B2
(en)
|
2006-11-03 |
2011-10-18 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
|
|
JP2010511692A
(ja)
|
2006-12-05 |
2010-04-15 |
アイゲート ファーマ エスエーエス |
イオントフォレシスを通じての核酸の強化された網膜送達
|
|
US20090010948A1
(en)
|
2006-12-15 |
2009-01-08 |
The University Of Hong Kong |
Anti-tumor vaccines delivered by dendritic cells devoid of interleukin-10
|
|
US8530436B2
(en)
|
2007-01-29 |
2013-09-10 |
Transderm, Inc. |
Methods and compositions for transdermal delivery of nucleotides
|
|
WO2008109353A1
(en)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting map2k gene expression and uses thereof
|
|
US20080311040A1
(en)
|
2007-03-06 |
2008-12-18 |
Flagship Ventures |
METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA
|
|
WO2008124634A1
(en)
*
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Polymer-encapsulated reverse micelles
|
|
EP2170395A1
(en)
|
2007-07-02 |
2010-04-07 |
Wyeth LLC |
Modulators of axl for use in treating bone disorders
|
|
US9884899B2
(en)
|
2007-07-06 |
2018-02-06 |
Promedior, Inc. |
Methods for treating fibrosis using CRP antagonists
|
|
WO2009020344A2
(en)
|
2007-08-06 |
2009-02-12 |
Postech Acad Ind Found |
Small interfering rnas (sirnas) controlling multiple target genes and method for preparing the same
|
|
EP2186528B1
(en)
|
2007-08-06 |
2014-03-19 |
Senju Pharmaceutical Co., Ltd. |
Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
|
|
CA2697043A1
(en)
*
|
2007-08-21 |
2009-02-26 |
Virginia Commonwealth University Intellectual Property Foundation |
Methods and compositions for treatment or prevention of radiation-induced fibrosis
|
|
ES2617877T3
(es)
|
2007-08-27 |
2017-06-20 |
1Globe Health Institute Llc |
Composiciones de ARN interferente asimétrico y uso de las mismas
|
|
US20090131360A1
(en)
|
2007-10-02 |
2009-05-21 |
Rxi Pharmaceuticals, Corp. |
Tripartite RNAi constructs
|
|
US8614309B2
(en)
|
2007-10-03 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
Double-stranded RNA directed to CASP2 and methods of use thereof
|
|
KR101889518B1
(ko)
*
|
2007-10-04 |
2018-08-17 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
마이크로ＭＩＲｓ
|
|
US7935816B2
(en)
|
2007-10-25 |
2011-05-03 |
Gene Tools, Llc |
Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
|
|
EP4074344A1
(en)
*
|
2007-12-04 |
2022-10-19 |
Arbutus Biopharma Corporation |
Targeting lipids
|
|
KR100949791B1
(ko)
*
|
2007-12-18 |
2010-03-30 |
이동기 |
오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
|
|
EP2242854A4
(en)
|
2008-01-15 |
2012-08-15 |
Quark Pharmaceuticals Inc |
COMPOUNDS AND USES THEREOF
|
|
JP5697993B2
(ja)
|
2008-02-11 |
2015-04-08 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
修飾ＲＮＡｉポリヌクレオチドおよびその使用
|
|
WO2009109665A1
(en)
|
2008-03-07 |
2009-09-11 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
|
EP2274425A2
(en)
|
2008-04-11 |
2011-01-19 |
Alnylam Pharmaceuticals Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
|
WO2010004435A2
(en)
|
2008-07-09 |
2010-01-14 |
Aspreva International Ltd. |
Formulations for treating eye disorders
|
|
US20110218334A1
(en)
|
2008-07-11 |
2011-09-08 |
Alnylam Pharmaceuticals, Inc. |
PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
|
|
EP2313505A2
(en)
|
2008-07-15 |
2011-04-27 |
F. Hoffmann-La Roche AG |
Compositions and methods for inhibiting expression of tgf-beta receptor genes
|
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
|
CA2731779A1
(en)
|
2008-07-24 |
2010-01-28 |
Rxi Pharmaceuticals Corporation |
Rnai constructs and uses therof
|
|
KR101877698B1
(ko)
|
2008-08-25 |
2018-07-12 |
엑스칼리아드 파마슈티컬즈, 인코포레이티드 |
결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도
|
|
WO2010027830A2
(en)
|
2008-08-25 |
2010-03-11 |
Excaliard Pharmaceuticals, Inc. |
Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases
|
|
US8946172B2
(en)
|
2008-08-25 |
2015-02-03 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to CTGF
|
|
EP3375451A1
(en)
|
2008-08-25 |
2018-09-19 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to ctgf
|
|
US20110288147A1
(en)
|
2008-09-22 |
2011-11-24 |
Bob Dale Brown |
Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop
|
|
CA2753338A1
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
|
US8691971B2
(en)
|
2008-09-23 |
2014-04-08 |
Scott G. Petersen |
Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
|
|
US8822425B2
(en)
|
2008-11-14 |
2014-09-02 |
Antisense Pharma Gmbh |
Dosage of oligonucleotides suitable for the treatment of tumors
|
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
|
MX2011005851A
(es)
|
2008-12-04 |
2011-07-29 |
Opko Opthalmics Llc |
Composiciones y metodos para la inhibicion selectiva de isoformas vegf proangiogenicas.
|
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
US9080186B2
(en)
|
2009-05-16 |
2015-07-14 |
Agave Pharma, Incorporated |
Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules
|
|
US8486909B2
(en)
*
|
2009-06-24 |
2013-07-16 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
|
|
WO2011041897A1
(en)
|
2009-10-06 |
2011-04-14 |
Angiochem Inc. |
Compositions and methods for the transport of therapeutic agents
|
|
EP2542058B1
(en)
|
2010-03-02 |
2018-10-10 |
RXi Pharmaceuticals Corporation |
Effective sensitizing dose of a gelled immunomodulating topical composition
|
|
WO2011109698A1
(en)
|
2010-03-04 |
2011-09-09 |
Rxi Pharmaceuticals Corporation |
Formulations and methods for targeted delivery to phagocyte cells
|
|
EP3578183B1
(en)
|
2010-03-24 |
2021-09-08 |
Phio Pharmaceuticals Corp. |
Rna interference in ocular indications
|
|
AU2011232365A1
(en)
|
2010-03-24 |
2012-10-25 |
Rxi Pharmaceuticals Corporation |
RNA interference in dermal and fibrotic indications
|
|
RU2615143C2
(ru)
|
2010-03-24 |
2017-04-04 |
Адвирна |
Самодоставляющие PHKi соединения уменьшенного размера
|
|
US8932575B2
(en)
|
2010-09-21 |
2015-01-13 |
University Of Miami |
Compositions and methods for inducing migration by dendritic cells and an immune response
|
|
CN103380145B
(zh)
|
2010-12-17 |
2016-10-12 |
生物控股有限公司 |
人类抗-sod1抗体
|
|
EP2670411B1
(en)
|
2011-02-02 |
2019-04-10 |
Excaliard Pharmaceuticals, Inc. |
Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars
|
|
US20140072613A1
(en)
|
2012-09-10 |
2014-03-13 |
Cynthia Lander |
Compositions and Methods for Treating Cutaneous Scarring
|
|
US9862777B2
(en)
|
2013-05-28 |
2018-01-09 |
Vib Vzw |
Single domain antibodies against SOD1 and their use in medicine
|
|
FI3702466T3
(fi)
|
2013-08-27 |
2023-03-23 |
Res Inst Nationwide Childrens Hospital |
Valmisteita ja menetelmiä amyotrofisen lateraaliskleroosin hoitoon
|
|
WO2015038892A1
(en)
|
2013-09-13 |
2015-03-19 |
Moderna Therapeutics, Inc. |
Polynucleotide compositions containing amino acids
|
|
JP6772062B2
(ja)
|
2013-12-02 |
2020-10-21 |
フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． |
癌の免疫療法
|
|
JP6883987B2
(ja)
|
2013-12-04 |
2021-06-09 |
フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． |
化学修飾されたオリゴヌクレオチドを利用する創傷治癒の処置のための方法
|
|
EP3137119B1
(en)
|
2014-04-28 |
2020-07-01 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using a nucleic acid targeting mdm2
|
|
CA2947619A1
(en)
|
2014-05-01 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
|
|
KR102506169B1
(ko)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
|
US20180263925A1
(en)
|
2014-12-03 |
2018-09-20 |
Rxi Pharmaceuticals Corporation |
Methods for the treatment of alopecia areata utilizing gene modulation approaches
|
|
JP6892433B2
(ja)
|
2015-04-03 |
2021-06-23 |
ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ |
十分に安定化された非対称ｓｉｒｎａ
|
|
DK3277814T3
(da)
|
2015-04-03 |
2020-08-24 |
Univ Massachusetts |
Oligonukleotidforbindelser til målretning mod huntingtin-mrna
|
|
DK3277815T3
(da)
|
2015-04-03 |
2021-12-13 |
Univ Massachusetts |
Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
|
|
CA2991598A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
|
WO2017044815A1
(en)
|
2015-09-11 |
2017-03-16 |
Rxi Pharmaceuticals Corporation |
Methods for treating skin disorders and conditions utilizing haptens
|
|
CA2998589A1
(en)
|
2015-09-14 |
2017-03-23 |
Compass Therapeutics Llc |
Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-.beta.
|
|
WO2017070151A1
(en)
|
2015-10-19 |
2017-04-27 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
|
|
WO2017173453A1
(en)
|
2016-04-01 |
2017-10-05 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
|
JP7167059B2
(ja)
|
2017-04-19 |
2022-11-08 |
フィオ ファーマシューティカルズ コーポレーション |
核酸化合物の局所送達
|
|
CA3070747A1
(en)
|
2017-08-07 |
2019-02-14 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides
|